Case Reports: Subtrochanteric Femoral Stress Fractures after Prolonged Alendronate Therapy

Simultaneous bilateral atypical femoral fractures after alendronate therapy.

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

We carried out a retrospective review over ten months of patients who had presented with a low-energy subtrochanteric fracture. We identified 13 women of whom nine were on long-term alendronate therapy and four were not. The patients treated with alendronate were younger, with a mean age of 66.9 years (55 to 82) vs 80.3 years (64 to 92) and were more socially active. The fractures sustained by ...

Alendronate-associated femoral insufficiency fractures and femoral stress reactions.

PURPOSE To report characteristics and outcomes of 8 patients who underwent intramedullary nailing for alendronate-associated femoral insufficiency fractures. METHODS Records of 7 women and one man aged 54 to 91 (mean, 72) years who underwent intramedullary nailing for spontaneous or low-energy, alendronateassociated femoral insufficiency fractures were retrospectively reviewed. Contralateral ...

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

BACKGROUND Subtrochanteric insufficiency fractures in post-menopausal patients have not been commonly reported in the literature. A recent increase in the incidence of such fractures occurring in patients while on alendronate therapy led us to conduct a retrospective review of these patients in our institution. METHODS Seventeen patients, with a mean age of 66 years, sustained low energy subt...

Spontaneous Subtrochanteric Femoral Stress Fracture Related to Alendronate : A Case Report

UNLABELLED Spontaneous atypical fractures of the femur have been reported in patients on long-term antiresorptive bisphosphonate therapy. Here, we report a case of subtrochanteric stress fracture in a seventy-year-old female patient on long-term alendronate therapy, and accompanying management challenges. Potential measures to prevent this complication of antiresorptive treatment for osteoporos...